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Background
KSHV-associated multicentric Castleman’s disease
(MCD) is a frequently fatal lymphoproliferative disorder
characterized by inflammatory flares of fever, cytope-
nias, hypoalbuminemia, hyponatremia, and splenome-
galy. Most cases occur in HIV-infected patients. KHSV
viral interleukin-6 (vIL-6), human IL-6 (hIL-6), and pos-
sibly other proinflammatory cellular cytokines are
believed to contribute to the pathophysiology of MCD
flares.
Methods
We identified MCD patients with clinical flares. KSHV
viral load (VL) in peripheral blood mononuclear cells,
vIL-6, and the cellular cytokines IL-6, IL-1b, IL-8,
IL-10, IL-12p70, interferon gamma, and tumor necrosis
factor alpha were measured during flares and remis-
sions to identify parameters best characterizing flares.
T h ea s s a yf o rv I L - 6w a sm o d i f i e df r o mA o k iY .e ta l . ,
Blood, 97, 2526, 2001; the cutoff of detection was 1560
pg/ml. Factors statistically associated with flares
(p<0.01) were explored in relationship to common
disease manifestations with multiple linear regression
models.
Results
20 patients (18 male, 2 female) were studied during 33
flares (range 1-3 per patient) and, in 18 patients, remission
with therapy. Median (range) values of key parameters
during flares included hemoglobin 9.9 mg/dL (6.8-14.4);
platelet count 97 K/μL (6-377); sodium 133 mEq/L (127-
143); albumin 2.7 mg/dL (1.2-3.9); spleen size 14.5 cm (9-
28); temperature 38°C (36.1-40.5); CD4 count 240 cells/μL
(24-1319); HIV VL <50 copies/mL (<50-64100). Flares
were associated with elevated KSHV VL (median 23448
copies/mL; range 0-3913043; p<0.0001 compared with
remission), vIL-6 (2575 pg/mL; <1560-20497; p=0.0039),
hIL-6 (24.2 pg/mL; 1.4-171.5; p=0.0034), hIL-10 (783.9 pg/
mL; 2.8-26021; p=0.0027), and hIL-1b (1.3 pg/mL; 0-11.3;
p=0.0074). In two of the 33 flares vIL-6 was elevated but
hIL-6 was not; in 14 hIL-6 was elevated but vIL6 was
undetectable; and in 15 both were elevated. Neither was
initially elevated in 2 flares, but hIL-6 later became ele-
vated in both. Disease manifestations did not differ among
flares with differing vIL-6/hIL-6 profiles. In multiple
regression analysis, elevated KSHV VL was the strongest
predictor of level of hemoglobin (p<0.0001), sodium
(p<0.0001), albumin (p<0.0001), and spleen size
(p=0.0002); hIL-6 the strongest predictor of thrombocytes
(p=0.0011), and KSHV and hIL-6 together the strongest
predictors of body temperature (p<0.0001). For hemoglo-
bin, but not other parameters, vIL-6 and hIL-6 in combi-
nation were stronger predictors than either independently
(p=0.0002), though less strong than KSHV VL alone.
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KSHV activity, vIL-6 production, and associated human
hIL-6 dysregulation are key determinants of the clinical
manifestations of MCD. vIL-6 and hIL-6 each appear
sufficient to induce flares without the other. hIL-10 and
hIL-1ß are also elevated in MCD flares, but their contri-
bution to symptomatology remains to be determined.
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